Prefilled syringes are the standard of care in industrialized countries. However this technology is not used in developing countries (except through private markets) because of cost and logistical issues.
Uniject™ is a compact, pre-filled autodisable injection device (CPAD) originally developed by PATH to facilitate access to vaccines and drugs in developing countries. Uniject™ provides a single dose injection without requiring preparation, and with reduced volume / waste. It already has been used in different contexts to inject tetanus toxoid and hepatitis B vaccines. A new presentation of the liquid Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus influenzae type b (DTP-HepB-Hib) pentavalent vaccine presented in a UnijectTM device is currently under development by Crucell.
Crucell asked AMP to assess the acceptability, feasibility, and optimal method of using UnijectTM for pentavalent in two Gavi-eligible countries (Senegal and Vietnam).
This study included two components:
- An assessment of anthropological issues
- An assessment of logistical / programmatic issues